Giuseppe Procopio

Giuseppe Procopio

Milan, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 354 publications

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

Reducing the burden of active surveillance monitoring examinations in prostate cancer: Insights from real-world data to inform clinical practice.

Journal: Tumori
Published: August 25, 2026

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 22, 2026

Local treatment of the primary tumour in mHSPC in the ARPI era: incremental value or overtreatment?

Local treatment of the primary tumour in mHSPC in the ARPI era: incremental value or overtreatment?

Journal: Expert review of anticancer therapy
Published: June 10, 2026

Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.

Lynch syndrome-associated urothelial carcinoma: clinical and molecular findings from a single-institution cohort.

Journal: Familial cancer
Published: June 01, 2026

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Detection of Homologous Recombination Repair Gene Mutations by Tumor Tissue and Circulating Tumor DNA Testing in Prostate Cancer in the Phase III PROpel Trial.

Journal: JCO precision oncology
Published: May 11, 2026

177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

177Lu-PSMA-617 radioligand therapy as an immune modulator in prostate cancer.

Journal: Expert review of anticancer therapy
Published: May 06, 2026

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

Journal: Tumori
Published: May 04, 2026

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Predicting efficacy in patients with locally advanced/metastatic urothelial carcinoma (mUC) treated with immunotherapy using explainable machine learning approaches: the SamUR-AI trial on behalf of the Meet-URO group.

Journal: ESMO real world data and digital oncology
Published: April 03, 2026

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Journal: Cancer metastasis reviews
Published: April 02, 2026

Never Stop the Pressure: Maintaining Angiogenesis Inhibition Beyond Progression in Metastatic Renal Cell Carcinoma.

Never Stop the Pressure: Maintaining Angiogenesis Inhibition Beyond Progression in Metastatic Renal Cell Carcinoma.

Journal: JCO oncology practice
Published: March 31, 2026

Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets.

Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets.

Journal: ESMO open
Published: March 30, 2026

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis.

Journal: Targeted oncology
Published: March 30, 2026
Showing 1-12 of 354

Last Updated: 09/26/2026